The research to find better medicaments against Alzheimer’s disease is going on continuos. New drugs are under different levels of study. Galanthamine, an acetylcholinesterase inhibitor, is in phase III (clinical trials) in Austria. In this communication, the results of its determination in biological fluids and pharmaceutical preparations using capillary zone electrophoresis are presented.

Keywords: Galanthamine; Alzheimer’s disease medicaments; Acetylcholinesterase inhibitor; Capillary zone electrophoresis